Skip to main content

Day: September 21, 2020

NuCana Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) — NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889 American Depositary Shares (“ADSs”), at a public offering price of $4.50 per ADS, which includes 2,333,333 additional ADSs issued upon the exercise in full of the underwriters’ option to purchase additional ADSs. The aggregate gross proceeds to NuCana from the offering, before deducting underwriting discounts and commissions and estimated offering expenses were $80.5 million. All of the ADSs in the offering were sold by NuCana.Jefferies, Cowen, William Blair, and Truist Securities acted as joint book-running managers for the offering.The securities...

Continue reading

Aimco Cares Charity Golf Classic Raises $340,000 for Military Causes, Scholars and Local Nonprofits

Denver, CO, Sept. 21, 2020 (GLOBE NEWSWIRE) — With the help of its longstanding business partners, Aimco grossed more than $340,000 for beneficiaries of the 17th Annual Aimco Cares Charity Golf Classic.  The tournament, held August 6 at the Sanctuary golf club in Sedalia, CO, is consistently the highest grossing tournament at the course, raising more than $5.3 million in its 17-year history.The Tragedy Assistance Program for Survivors (TAPS) is the front-line resource for military families grieving the loss of a loved one who made the ultimate sacrifice while serving our country. TAPS provides 24/7 comfort and care through a national network of peer-based emotional support, case work assistance, crisis intervention, and grief and trauma resources.Project Sanctuary helps military families reconnect after a soldier returns from overseas...

Continue reading

Standard Lithium Marks Commencement of Operations at Arkansas Plant With a Virtual Ribbon Cutting Ceremony

EL DORADO, Ark., Sept. 21, 2020 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), an innovative technology and lithium project development company, today marked the official commencement of operations at the Company’s Arkansas LiSTR Direct Lithium Extraction facility, with a virtual ribbon-cutting and video walk-through tour of the plant. Arkansas Governor Asa Hutchinson, Senator’s John Boozman and Tom Cotton, Representative Bruce Westerman, and local officials joined Standard Lithium CEO Robert Mintak and LANXESS Corp. CEO and President Antonis Papadourakis for the virtual event. A recording of the event can be found on the Company’s YouTube channel, website and its other social media outlets.Standard Lithium CEO Robert Mintak stated, “It was always our intention...

Continue reading

Teladoc Health Is Providing Free Virtual Health Care Services to Those Impacted by Hurricane Sally

PURCHASE, NY, Sept. 21, 2020 (GLOBE NEWSWIRE) — Teladoc Health (NYSE: TDOC), the global leader in virtual care, is providing free, 24/7 general medical telehealth visits to residents, first responders and others directly impacted by Hurricane Sally and the devastating floods that have affected the area as a result. Individuals from the hardest hit areas in Alabama and Florida, as well as those located in Georgia and the Carolinas who are now being displaced can seek treatment from a board-certified, state licensed physician for any non-emergency illness by calling Teladoc directly at 855-225-5032.“Especially during this hurricane season, as communities are already navigating an active pandemic, we want to make sure that those who are faced with the devastation of natural disasters are keeping their health front and center and know...

Continue reading

RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTION

RECORDATI LICENSES AN INNOVATIVE EPINEPHRINE NASAL SPRAY IN DEVELOPMENT FOR ANAPHYLAXIS PREVENTIONMilan, 21 September, 2020 – Recordati announces the signing of an exclusive license agreement with ARS Pharmaceuticals, a private U.S. company, for the commercialization in the European Union, Iceland, Liechtenstein, Norway, Switzerland, United Kingdom, Russia/CIS, Turkey, Middle East and French-speaking African countries, of ARS-1, an epinephrine nasal spray in late-stage development for the emergency treatment of severe allergic reactions that can lead to anaphylaxis. Under the terms of the agreement an upfront payment is due by Recordati upon signature of the contract and further milestone payments are linked to the regulatory process and commercial performance. Anaphylaxis is a severe, generalized allergic reaction, characterized...

Continue reading

RECORDATI: LICENZA PER SPRAY NASALE INNOVATIVO A BASE DI EPINEFRINA PER LA PREVENZIONE DELL’ANAFILASSI

RECORDATI: LICENZA PER SPRAY NASALE INNOVATIVO A BASE DI EPINEFRINA PER LA PREVENZIONE DELL’ANAFILASSIMilano, 21 settembre 2020 – Recordati annuncia la firma di un accordo esclusivo di licenza con ARS Pharmaceuticals, una società farmaceutica privata basata negli Stati Uniti d’America, per la commercializzazione nell’Unione Europea, Islanda, Liechtenstein, Norvegia, Svizzera, Regno Unito, Russia/CIS, Turchia, Medio Oriente a i paesi africani francofoni, di ARS-1, uno spray nasale a base di epinefrina, in fase avanzata di sviluppo per il trattamento in emergenza di reazioni allergiche gravi che potrebbero portare all’anafilassi. Le condizioni dell’accordo prevedono che sia dovuto un pagamento up-front alla firma del contratto oltre al pagamento di milestones futuri associati al processo regolatorio e traguardi commerciali.L’anafilassi...

Continue reading

Provectus Biopharmceuticals Highlights Stage IV M1d Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

Complete response of all injected lesionsRegression of non-injected inguinal node, lung, and brain metastasesExpanded data set of trial subject providedKNOXVILLE, TN, Sept. 21, 2020 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today highlighted the clinical outcome of a Stage IV M1d patient (Subject 0602) in the Company’s Phase 1b/2 study of small molecule autolytic cancer immunotherapy PV-10, an injectable formulation of Provectus’ proprietary rose bengal disodium (RBD), in combination with KEYTRUDA (pembrolizumab) for the treatment of advanced cutaneous melanoma in patients refractory to immune checkpoint blockade (CB). Preliminary response, safety, and immune correlative data from this CB-Refractory Cohort were previously presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, held online from...

Continue reading

Kentucky First Federal Bancorp Releases Fiscal Year Results

HAZARD, Ky. and FRANKFORT, Ky. and DANVILLE, Ky. and LANCASTER, Ky., Sept. 21, 2020 (GLOBE NEWSWIRE) — Kentucky First Federal Bancorp (Nasdaq: KFFB), (the “Company”) the holding company for First Federal Savings and Loan Association of Hazard and First Federal Savings Bank of Kentucky, announced that a non-cash $13.6 million goodwill impairment charge led to a reported loss of $13.3 million or $1.61 per common share for the quarter ended June 30, 2020. This compares to net income of $300,000 or $0.04 per common share for the quarter ended June 30, 2019. The Company reported a net loss of $12.5 million or $1.52 per common share for the twelve months ended June 30, 2020, compared to net earnings of $812,000 or $0.10 per common share for the twelve months ended June 30, 2019.The Company recorded a goodwill impairment charge, which...

Continue reading

Centerra Gold 2020 Third Quarter Results Conference Call and Webcast

TORONTO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Centerra Gold Inc. (TSX: CG) will host a conference call and webcast of its 2020 third quarter financial and operating results at 9:00AM Eastern time on Wednesday November 4, 2020. The results are scheduled to be released before the market opens on Wednesday, November 4, 2020.North American participants may access the call toll-free at +1 (800)-935-9319.International participants may access the call at +1 (416)-981-9009.The conference call is being webcast by Intrado and can be accessed live at Centerra Gold’s website at www.centerragold.com. Presentation slides of the third quarter results will also be accessible on Centerra Gold’s website at www.centerragold.comAn audio recording of the call will be available approximately two hours after the call via telephone until midnight Eastern...

Continue reading

L.B. Foster Company to Host Investor Call Regarding the Sale of IOS Test & Inspection Services Business

PITTSBURGH, Sept. 21, 2020 (GLOBE NEWSWIRE) — L.B. Foster Company (NASDAQ: FSTR), today announced that it will host a conference call to discuss the sale of the IOS Test & Inspection Services Business on Monday, September 28, 2020 at 4:00 p.m. Eastern Time.  A brief presentation will be available on the Company’s website under the Investor Relations page immediately before the conference call begins.Those wishing to participate via the telephone may dial in at (833) 614-1392 (U.S. & Canada) or (914) 987-7113 (International).  Those wishing to participate via the webcast should access the call through L.B. Foster’s Investor Relations page of the company’s website (www.lbfoster.com).A conference call replay will be available through October 5, 2020.  To access the replay, please dial (855) 859-2056 (U.S. & Canada) or...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.